Poor outcome in patients with acute leukemia on intensive chemotherapy and COVID-19

Concurrent Diagnosis of Acute Myeloid Leukemia and COVID-19: A Management Challenge

“…Ferrara et al have described ten COVID-19 patients with AML, seven of which developed rapid worsening of respiratory function, seven required modifications in the hematological treatment, five died after a median of eight days and death was COVID-19 related in all cases [7]. In addition, Núñez-Torrón et al have described four patients with AML and COVID-19, three of which developed refractory acute respiratory distress syndrome (ARDS) and eventually died [8]. Of note, none of the patients in these two studies received remdesivir or COVID-19 convalescent plasma.…”

Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia

“…COVID-19 is a life threatening disease, caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and patients with undergoing treatment for hematologic malignancies including hematopoietic stem cell transplantation are considered to be at particular risk for fatal outcomes [1,2].…”

The impact of lockdown during the COVID-19 pandemic on newly acute myeloid leukemia patients: Single-centre comparative study between 2019 and 2020 cohorts in Madrid

“…The impact on outcomes in this group could be related with diagnosis delay, progression due to antineoplastic therapy discontinuation or other reasons. Furthermore, patients with haematological malignancies and COVID-19 present a higher risk of severe events and death [ 4 , 5 , 6 ], being AML one of the neoplasms with higher mortality rate [ 5 , 6 , 7 , 8 ].…”